Exelixis Announces Webcasts of Investor Conference Presentations in November
21 November 2018 - 8:05AM
Business Wire
- Presentations to be webcast on
www.exelixis.com -
Exelixis, Inc. (NASDAQ: EXEL) today announced
that Michael M. Morrissey, Ph.D., the company’s President and
Chief Executive Officer, will provide an overview of the company at
the following investor conferences in November:
- The 30th Annual Piper Jaffray
Healthcare Conference: Exelixis is scheduled to present
at 11:00 AM EST / 8:00 AM PST on Tuesday,
November 27, 2018 in New York.
- Evercore ISI
HealthConX: Exelixis is scheduled to present at 2:00
PM EST / 11:00 AM PST on Wednesday, November
28, 2018 in Boston.
To access the webcast links, log
onto www.exelixis.com and proceed to the News &
Events / Event Calendar page under the Investors & Media
heading. Please connect to the company’s website at least 15
minutes prior to each presentation to ensure adequate time for any
software download that may be required to listen to the webcasts.
Replays will also be available at the same location for 14
days.
About Exelixis
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially
successful, oncology-focused biotechnology company that strives to
accelerate the discovery, development and commercialization of new
medicines for difficult-to-treat cancers. Following early work in
model genetic systems, we established a broad drug discovery and
development platform that has served as the foundation for our
continued efforts to bring new cancer therapies to patients in
need. We discovered our three commercially available products,
CABOMETYX® (cabozantinib), COMETRIQ® (cabozantinib) and COTELLIC®
(cobimetinib), and have entered into partnerships with leading
pharmaceutical companies to bring these important medicines to
patients worldwide. Supported by revenues from our marketed
products and collaborations, we are committed to prudently
reinvesting in our business to maximize the potential of our
pipeline. We are supplementing our existing therapeutic assets with
targeted business development activities and internal drug
discovery – all to deliver the next generation of Exelixis
medicines and help patients recover stronger and live longer.
Exelixis is a member of Standard & Poor’s (S&P) MidCap 400
index, which measures the performance of profitable mid-sized
companies. For the second consecutive year, Exelixis earned a
spot on Deloitte’s Technology Fast 500 list, a yearly award program
honoring the 500 fastest-growing companies over the past four
years. For more information about Exelixis, please visit
www.exelixis.com, follow @ExelixisInc on Twitter or like
ExelixisInc on Facebook.
Exelixis, the Exelixis logo, CABOMETYX,
COMETRIQ and COTELLIC are registered U.S. trademarks.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181120005565/en/
Investors Contact:Susan HubbardEVP, Public Affairs
andInvestor RelationsExelixis,
Inc.650-837-8194shubbard@exelixis.com
Media Contact:Hal MackinsFor Exelixis,
Inc.415-994-0040hal@torchcommunications.com
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From Apr 2024 to May 2024
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From May 2023 to May 2024